Somatostatin-omeprazole combination therapy improves haemostasis, cuts rebleeding in non-variceal GI bleeding

Acute upper gastrointestinal bleeding (AUGIB), particularly non-variceal upper gastrointestinal bleeding (NVUGIB), remains a critical clinical condition associated with high morbidity and mortality. Current standard-of-care often involves proton pump inhibitors (PPIs) like omeprazole to reduce gastric acid secretion, but rebleeding rates can still be substantial. Somatostatin, an endogenous peptide, is known for its inhibitory effects on various gastrointestinal secretions and motility, making it a candidate for combination therapy to enhance haemostasis and improve clinical outcomes beyond monotherapy.

Researchers developed a reproducible retrospective workflow to evaluate combination pharmacological therapy using electronic medical record (EMR) data. This protocol involved systematic database querying, application of specific inclusion and exclusion criteria, and group allocation based on treatment records. They then applied this workflow to assess the efficacy of somatostatin combined with omeprazole versus omeprazole alone in patients with NVUGIB. The study systematically extracted predefined clinical and laboratory outcomes, analyzing the data using a stepwise statistical approach to compare haemostatic outcomes, rebleeding rates, and clinical recovery between the treatment groups.

The retrospective analysis demonstrated that combination therapy with somatostatin and omeprazole was associated with significantly improved haemostatic outcomes compared to omeprazole monotherapy. Patients receiving the combination also experienced reduced rebleeding rates, indicating a more sustained therapeutic effect. Furthermore, the study observed enhanced clinical recovery in the combination therapy group. Importantly, these benefits were achieved without an increase in adverse events, suggesting a favorable safety profile for the combined approach. The findings, while hypothesis-generating, highlight the potential synergistic effects of combining an anti-secretory peptide with a proton pump inhibitor in managing NVUGIB. The study primarily focused on the utility of its retrospective data analysis workflow but yielded compelling preliminary clinical associations.

Combination therapy with somatostatin and omeprazole was associated with improved haemostatic outcomes, reduced rebleeding rates, and enhanced clinical recovery compared with omeprazole alone, without an increase in adverse events.